• Mashup Score: 21
    Clinical trial design for non-muscle-invasive bladder cancer - 11 month(s) ago

    The heterogeneous nature of non-muscle-invasive bladder cancer is a challenge for clinical trial design. Careful consideration in clinical trial design, choice of end points and adequate patient characterization is important when evaluating new therapies.

    Source: www.nature.com
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of DrTanWP
      DrTanWP

      RT @drtanws: Thank you @NatRevUrol for publishing our thoughts on clinical trial design for NMIBC https://t.co/I6yB5AjZYv @EmmaHall71 @Ur…

  • Mashup Score: 4
    NYU School of Medicine CME - 1 year(s) ago

    The primary goal of this conference is designed to provide the urologist, radiologist, nurse practitioner or physician assistant with a comprehensive review of controversies and advances in prostate imaging, prostate biopsy, screening biomarkers, molecular markers for risk stratification, and partial gland ablation (PGA) of prostate cancer that impact disease management. Optimizing selection of…

    Source: www.highmarksce.com
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of DrTanWP
      DrTanWP

      Don't miss out on the 'Advances in Screening, Detection and Treatment of Prostate Cancer' course @NYUUrology @Perlmutter_CC featuring Dr Lepor, @tanejauro, @PeterPintoMD, @EmbertonMark, @dr_coops, @arosenkrantzmd, @RadioDoctorKatz. Register now: https://t.co/AdNA0TCj0h https://t.co/dcqrCz8AZL

  • Mashup Score: 8
    Please wait whilst we redirect you - 1 year(s) ago

    About ScienceDirectRemote accessShopping cartAdvertiseContact and supportTerms and conditionsPrivacy policyWe use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.Copyright © 2023 Elsevier B.V. or its licensors or contributors. ScienceDirect® is a registered trademark of Elsevier B.V.ScienceDirect® is a registered trademark…

    Source: www.sciencedirect.com
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of DrTanWP
      DrTanWP

      Excited to share our salvage WG cryoablation series for radiation-resistant/recurrence PCa @EurUrolOncol ❄️BRFS was 81% at 2 yr and 71% at 5 yr. ❄️Patients with PSA ng/ml >/= 0.5 eventually develop BCR. @ThomasPolascik @DukeUrology @denis_seguier https://t.co/syEsY4AxRO https://t.co/nnRSVbL6TG

  • Mashup Score: 0
    Hyperthermia Improves Solubility of Intravesical Chemotherapeutic Agents - 1 year(s) ago

    Nearly 70% of all new cases of bladder cancer are non-muscle invasive disease, the treatment for which includes transurethral resection followed by intravesical therapy. Unfortunately, recurrence rates approach 50% in part due to poor intravesical drug …

    Source: PubMed Central (PMC)
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of DrTanWP
      DrTanWP

      @DominicGrimberg, @AnkeetShahMD and #BrantInman @DukeUrology looked at the solubility of gemcitabine at room temperature @BladderCaJrnl https://t.co/i8atSqfWDw

  • Mashup Score: 3
    Helix - 1 year(s) ago

    Helix is your guide to prostate cancer genetic testing. It is a provider toolkit with patient intake questions, recommendations, and a comprehensive resource library.

    Source: www.helix.guide
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of DrTanWP
      DrTanWP

      RT @ChapinMD: @LoebStacy speaking on Germline testing in prostate cancer. Takeaway:Use https://t.co/TDWxGs75HQ to help determine who shou…

  • Mashup Score: 1
    Partial gland cryoablation for prostate cancer — where are we? - 1 year(s) ago

    The treatment landscape for localized prostate cancer is rapidly evolving to achieve oncological disease control, simultaneously preserving gastrointestinal and genitourinary function. Focal therapy using cryoablation is an emerging treatment for prostate cancer. Short-term and intermediate-term clinical data on focal cryoablation therapy in prostate cancer have shown promising oncological and…

    Source: www.nature.com
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of DrTanWP
      DrTanWP

      #Twittorial on our recent partial gland cryoablation clinical outlook article @NatRevUrol @NYUUrology @Perlmutter_CC @nyulangone @FocalSociety #ProstateCancer #FocalTherapy #Cryoablation https://t.co/J3pnIKiazd https://t.co/wPlGL2PfuJ